This Ars Pharmaceuticals Inc. (NASDAQ: SPRY) report was produced by Stock Traders Daily. Over the past 20 years our metholdology has been refined to help identify strategies for both individual stocks ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 47.40% ...

In a report released today, Ryan Deschner from Raymond James maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report), with a ...

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) shot up 7.6% during mid-day trading on Monday after Raymond James raised their price target on the stock from $26.00 to $28.00.

Cantor Fitzgerald has recently initiated ARS Pharmaceuticals Inc (SPRY) stock to Overweight rating, as announced on August 20, 2024, according to Finviz. Earlier, on August 13, 2024, Raymond James had ...